About Court Report:  Each week we will report briefly on recently filed biotech and pharma cases.

Horizon Pharma, Inc. et al. v. Actavis Laboratories FL., Inc. et al.
3:15-cv-03322; filed May 13, 2015 in the District Court of New Jersey

• Plaintiffs:  Horizon Pharma, Inc.; Pozen Inc.
• Defendants:  Actavis Laboratories FL., Inc.; Actavis Pharma, Inc.; Actavis, Inc.

Horizon Pharma, Inc. et al. v. Dr. Reddy's Laboratories Inc. et al.
3:15-cv-03324; filed May 13, 2015 in the District Court of New Jersey

• Plaintiffs:  Horizon Pharma, Inc.; Pozen Inc.
• Defendants:  Dr. Reddy's Laboratories Inc.; Dr. Reddy's Laboratories Ltd.

Horizon Pharma, Inc. et al. v. Lupin Ltd. et al.
3:15-cv-03326; filed May 13, 2015 in the District Court of New Jersey

• Plaintiffs:  Horizon Pharma, Inc.; Pozen Inc.
• Defendants:  Lupin Ltd.; Lupin Pharmaceuticals Inc.

Horizon Pharma, Inc. et al. v. Mylan Pharmaceuticals Inc. et al.
3:15-cv-03327; filed May 13, 2015 in the District Court of New Jersey

• Plaintiffs:  Horizon Pharma, Inc.; Pozen Inc.
• Defendants:  Mylan Pharmaceuticals Inc.; Mylan Laboratories Ltd.; Mylan, Inc.

The complaints in these cases are substantially identical.  Infringement of U.S. Patent Nos. 8,852,636 ("Pharmaceutical Compositions for the Coordinated Delivery of NSAIDs" issued October 7, 2014), 8,858,996 (same title, issued October 14, 2014), in conjunction with defendants' filing of an ANDA to manufacture a generic version of Horizon's Vimovo® Delayed-Release (naproxen and esomeprazole magnesium, used to relieve the signs and symptoms of osteoarthritis, rheumatoid arthritis, and ankylosing spondylitis, and to decrease the risk of stomach (gastric) ulcers in patients at risk of developing stomach ulcers from treatment with non-steroidal anti-inflammatory drugs (NSAIDs)).  View the Actavis complaint here.

Senju Pharmaceutical Co., Ltd. et al. v. Innopharma Licensing, Inc. et al.
1:15-cv-03240; filed May 8, 2015 in the District Court of New Jersey

• Plaintiffs:  Senju Pharmaceutical Co., Ltd.; Bausch & Lomb Inc.; Bausch & Lomb Pharma Holdings Corp.
• Defendants:  Innopharma Licensing, Inc.; Innopharma Licensing, LLC; Innopharma, Inc.; Innopharma, LLC; Mylan Pharmaceuticals, Inc.; Mylan Inc.

Infringement of U.S. Patent Nos. 8,129,431 ("Aqueous Liquid Preparation Containing 2-amino-3-(4-bromobenzoyl)phenylacetic acid," issued March 6, 2012), 8,669,290 (same title, issued March 1, 2014), 8,754,131 (same title, issued June 17, 2014), 8,871,813 (same title, issued October 28, 2014), and 8,927,606 (same title, issued January 6, 2015) against Mylan, and the '606 patent against Innopharma, following a Paragraph IV certification as part of Innopharma's filing of an ANDA to manufacture a generic version of B&L's Prolensa® (bromfenac ophthalmic solution, used to treat postoperative inflammation and reduction of ocular pain in patients who have undergone cataract surgery).  View the complaint here.

Jazz Pharmaceuticals, Inc. v. Amneal Pharmaceuticals, LLC et al.
2:15-cv-03217; filed May 7, 2015 in the District Court of New Jersey

• Plaintiff:  Jazz Pharmaceuticals, Inc.
• Defendants:  Amneal Pharmaceuticals, LLC; Par Pharmaceutical, Inc.; Sun Pharmaceutical Industries Ltd.; Ohm Laboratories Inc.; Ranbaxy Inc.

Infringement of U.S. Patent No. 8,952,062 ("Microbiologically Sound and Stable Solutions of Gamma-Hydroxybutyrate Salt for the Treatment of Narcolepsy," issued February 10, 2015) following a Paragraph IV certification as part of defendants' filing of an ANDA to manufacture a generic version of Jazz's Xyrem® (sodium oxybate, used to treat narcolepsy).  View the complaint here.

Zoetis LLC et al. v. Roadrunner Pharmacy, Inc.
2:15-cv-03193; filed May 6, 2015 in the District Court of New Jersey

• Plaintiffs:  Zoetis LLC; Zoetis Services LLC; Zoetis US LLC
• Defendant:  Roadrunner Pharmacy, Inc.

Infringement of U.S. Patent Nos. 8,133,899 ("Pyrrolo[2,3-d]pyrimidine Compounds," issued March 13, 2012) and 8,987,283 (same title, issued March 24, 2015) based on Roadrunner's manufacture and sale of a oclacitinib free base product, sold to be equivalent to Zoetis' APOQUEL® (oclacitinib maleate, used for the treatment of pruritus and allergic reactions in dogs).  View the complaint here.